Effect of dihydropyrimidine dehydrogenase single nucleotide polymorphisms on prognosis of breast cancer patients with chemotherapy

Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate to guide patient selection for personalized cancer treatments. DPD (dihydropyrimidine dehydrogenase, encoded by DPYD gene) is the initial and rate-limiting enzyme of metabolic pathway of fluoropyrimidines, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Fengxia, Zhang, Huikun, Huang, Yong, Yang, Limin, Yu, Feng, Liu, Xiaoli, Fu, Li, Gu, Feng, Ma, Yongjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762379/
https://www.ncbi.nlm.nih.gov/pubmed/29340111
http://dx.doi.org/10.18632/oncotarget.23033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762379/
https://www.ncbi.nlm.nih.gov/pubmed/29340111
http://dx.doi.org/10.18632/oncotarget.23033

Ejemplares similares